Controlling the HIV/AIDS epidemic: Current status and global challenges

Frontiers in Immunology

Volumn 3, Issue AUG, 2012, Pages

  Demberg, Thorsten ^a   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Animal model; ART treatment; Global strategies; HIV pandemic; Prevention; Vaccine development

Indexed keywords

EID: 84874217824     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00250     Document Type: Review

References (269)

1. Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B., Sibeko, S., Mlisana, K. P., Omar, Z., Gengiah, T. N., Maarschalk, S., Arulappan, N., Mlotshwa, M., Morris, L., and Taylor, D. (2010). Effectiveness and safety of tenofovir gel, an antiretro-viral microbicide, for the prevention of HIV infection in women. Science 329, 1168-1174.
2. Abdool Karim, S. S., Richardson, B. A., Ramjee, G., Hoffman, I. F., Chirenje, Z. M., Taha, T., Kapina, M., Maslankowski, L., Coletti, A., Profy, A., Moench, T. R., Piwowar-Manning, E., Masse, B., Hillier, S. L., and Soto-Torres, L. (2011). Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 25, 957-966.
3. Adimora, A. A., and Auerbach, J. D. (2010). Structural interventions for HIV prevention in the United States. J. Acquir. Immune. Defic. Syndr. 55, S132-S135.
4. Agrati, C., D'Offizi, G., Gougeon, M. L., Malkovsky, M., Sacchi, A., Casetti, R., Bordoni, V., Cimini, E., and Martini, F. (2011). Innate gamma/delta T-cells during HIV infection: Terra relatively Incognita in novel vaccination strategies? AIDS Rev. 13, 3-12.
5. Ahlers, J. D., and Belyakov, I. M. (2010a). Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS. Trends Immunol. 31, 120-130.
6. Ahlers, J. D., and Belyakov, I. M. (2010b). Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood 115, 1678-1689.
7. Allers, K., Hutter, G., Hofmann, J., Loddenkemper, C., Rieger, K., Thiel, E., and Schneider, T. (2011). Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 117, 2791-2799.
8. Almond, D., Kimura, T., Kong, X., Swetnam, J., Zolla-Pazner, S., and Cardozo, T. (2010). Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop. AIDS Res. Hum. Retroviruses 26, 717-723.
9. Altfeld, M., Fadda, L., Frleta, D., and Bhardwaj, N. (2011). DCs and NK cells: critical effectors in the immune response to HIV-1. Nat. Rev. Immunol. 11, 176-186.
10. Ambrose, Z., Compton, L., Piatak, M. Jr. Lu, D., Alvord, W. G., Lubomirski, M. S., Hildreth, J. E., Lifson, J. D., Miller, C. J., and Kewalramani, V. N. (2008). Incomplete protection against simian immunodeficiency virus vaginal transmission in rhesus macaques by a topical antiviral agent revealed by repeat challenges. J. Virol. 82, 6591-6599.
11. Amuri, M., Mitchell, S., Cockcroft, A., and Andersson, N. (2011). Socio-economic status and HIV/AIDS stigma in Tanzania. AIDS Care 23, 378-382.
12. Ansari, A. A., Mayne, A. E., Takahashi, Y., and Pattanapanyasat, K. (2012). Incorporation of innate immune effector mechanisms in the formulation of a vaccine against HIV-1. Adv. Exp. Med. Biol. 780, 143-159.
13. Arthos, J., Cicala, C., Martinelli, E., Macleod, K., Van Ryk, D., Wei, D., Xiao, Z., Veenstra, T. D., Conrad, T. P., Lempicki, R. A., McLaughlin, S., Pascuccio, M., Gopaul, R., McNally, J., Cruz, C. C., Censoplano, N., Chung, E., Reitano, K. N., Kottilil, S., Goode, D. J., and Fauci, A. S. (2008). HIV-1 envelope protein binds to and signals through inte-grin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat. Immunol. 9, 301-309.
14. Arthos, J., Cicala, C., Selig, S. M., White, A. A., Ravindranath, H. M., Van Ryk, D., Steenbeke, T. D., Machado, E., Khazanie, P., Hanback, M. S., Hanback, D. B., Rabin, R. L., and Fauci, A. S. (2002). The role of the CD4 receptor versus HIV coreceptors in envelope-mediated apoptosis in peripheral blood mononuclear cells. Virolog y 292, 98-106.
15. Auvert, B., Taljaard, D., Lagarde, E., Sobngwi-Tambekou, J., Sitta, R., and Puren, A. (2005). Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS (1265). PLoS Med. 2:e298. doi: 10.1371/journal.pmed.0020298
16. Baba, T. W., Liska, V., Hofmann-Lehmann, R., Vlasak, J., Xu, W., Ayehunie, S., Cavacini, L. A., Posner, M. R., Katinger, H., Stiegler, G., Bernacky, B. J., Rizvi, T. A., Schnidt, R., Hill, L. R., Keeling, M. E., Lu, Y., Wright, J. E., Chou, T., and Ruprecht, R. M. (2000). Human neutralizing monoclonal antibodies of the IgG1subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6,200-206.
17. Bahey-El-Din, M., and Gahan, C. G. (2011). Lactococcus lactis-based vaccines: current status and future perspectives. Hum. Vaccin. 7, 106-109.
18. Barber, D. L., Andrade, B. B., Sereti, I., and Sher, A. (2012). Immune recon-stitution inflammatory syndrome: the trouble with immunity when you had none. Nat. Rev. Microbiol. 10, 150-156.
19. Barouch, D. H. (2010). Novel ade-novirus vector-based vaccines for HIV-1. Curr. Opin. HIV AIDS 5, 386-390.
20. Bastard, J. P., Soulié, C., Fellahi, S., Haïm-Boukobza, S., Simon, A., Katlama, C., Calvez, V., Marcelin, A. G., and Capeau, J. (2012). Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients. Antivir. Ther. doi: 10.3851/ IMP2093. [Epub ahead of print].
21. Beauliere, A., Toure, S., Alexandre, P. K., Kone, K., Pouhe, A., Kouadio, B., Journy, N., Son, J., Ettiegne-Traore, V., Dabis, F., Eholie, S., and Anglaret, X. (2010). The financial burden of morbidity in HIV-infected adults on antiretro-viral therapy in Cote d'Ivoire. PLoS ONE 5:e11213. doi: 10.1371/ journal.pone.0011213
22. Bednarik, D. P., and Folks, T. M. (1992). Mechanisms of HIV-1 latency. AIDS 6, 3-16.
23. Begay, O., Jean-Pierre, N., Abraham, C. J., Chudolij, A., Seidor, S., Rodriguez, A., Ford, B. E., Henderson, M., Katz, D., Zydowsky, T., Robbiani, M., and Fernandez-Romero, J. A. (2011). Identification of personal lubricants that can cause rectal epithelial cell damage and enhance HIV type 1 replication in vitro. AIDS Res. Hum. Retroviruses 27, 1019-1024.
24. Benjouad, A., Gluckman, J. C., Rochat, H., Montagnier, L., and Bahraoui, E. (1992). Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160. J. Virol. 66, 2473-2483.
25. Benmira, S., Bhattacharya, V., and Schmid, M. L. (2010). An effective HIV vaccine: a combination of humoral and cellular immunity? Curr. HIV Res. 8, 441-449.
26. Berzofsky, J. A., Ahlers, J. D., and Belyakov, I. M. (2001). Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 1, 209-219.
27. Birbeck, G. L., Kvalsund, M. P., Byers, P. A., Bradbury, R., Mang'ombe, C., Organek, N., Kaile, T., Sinyama, A. M., Sinyangwe, S. S., Malama, K., and Malama, C. (2011). Neuropsychiatric and socioeco-nomic status impact antiretroviral adherence and mortality in rural Zambia. Am. J. Trop. Med. Hyg. 85, 782-789.
28. Biswas, S., Chang, H., Sarkis, P. T., Fikrig, E., Zhu, Q., and Marasco, W. A. (2011). Humoral immune responses in humanized BLT mice immunized with West Nile virus and HIV-1 envelope proteins are largely mediated via human CD5(+) B cells. Immunology 134, 419-433.
29. Bode, C., Zhao, G., Steinhagen, F., Kinjo, T., and Klinman, D. M. (2011). CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines 10, 499-511.
30. Boesecke, C., and Vogel, M. (2011). HIV and hepatitis C co-infection: acute HCV therapy. Curr. Opin. HIV AIDS 6, 459-464.
31. Bostik, P., Takahashi, Y., Mayne, A. E., and Ansari, A. A. (2010). Innate immune natural killer cells and their role in HIV and SIV infection. HIV Ther. 4, 483-504.
32. Boudet, F., Girard, M., Theze, J., and Zouali, M. (1992). Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120. Int. Immunol. 4, 283-294.
33. Broder, S. (2010). The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral. Res. 85, 1-18.
34. Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., Del Rio, C., McElrath, M. J., Casimiro, D. R., Gottesdiener, K. M., Chodakewitz, J. A., Corey, L., and Robertson, M. N. (2008). Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881-1893.
35. Burton, D. R., Pyati, J., Koduri, R., Sharp, S. J., Thornton, G. B., Parren, P. W., Sawyer, L. S., Hendry, R. M., Dunlop, N., Nara, P. L., Lamacchia, M., Garratty, E., Stiehm, E. R., Bryson, Y. J., Cao, Y., Moore, J. P., Ho, D. D., and Barbas, C. F. III. (1994). Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024-1027.
36. Byakwaga, H., Kelly, M., Purcell, D. F., French, M. A., Amin, J., Lewin, S. R., Haskelberg, H., Kelleher, A. D., Garsia, R., Boyd, M. A., Cooper, D. A., and Emery, S. (2011). Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. J. Infect. Dis. 204, 1532-1540.
37. Cannon, P., and June, C. (2011). Chemokine receptor 5 knockout strategies. Curr. Opin. HIV AIDS 6, 74-79.
38. Caputo, A., Gavioli, R., Bellino, S., Longo, O., Tripiciano, A., Francavilla, V., Sgadari, C., Paniccia, G., Titti, F., Cafaro, A., Ferrantelli, F., Monini, P., Ensoli, F., and Ensoli, B. (2009). HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. Int. Rev. Immunol. 28, 285-334.
39. Carbone, A., Gloghini, A., Serraino, D., and Spina, M. (2009). HIV-associated Hodgkin lymphoma. Curr. Opin. HIV AIDS 4, 3-10.
40. Carr, J. K., Osinusi, A., Flynn, C. P., Gilliam, B. L., Maheshwari, V., and Zhao, R. Y. (2010). Two independent epidemics of HIV in Maryland. J. Acquir. Immune. Defic. Syndr. 54, 297-303.
41. Carrow, E. W., Vujcic, L. K., Glass, W. L., Seamon, K. B., Rastogi, S. C., Hendry, R. M., Boulos, R., Nzila, N., and Quinnan, G. V. Jr. (1991). High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas. AIDS Res. Hum. Retroviruses 7, 831-838.
42. Carter, D., and Reed, S. G. (2010). Role of adjuvants in modeling the immune response. Curr. Opin. HIV AIDS 5, 409-413.
43. Carvalho, F. T., Gonçalves, T. R., Faria, E. R., Shoveller, J. A., Piccinini, C. A., Ramos, M. C., and Medeiros, L. R. (2011). Behavioral interventions to promote condom use among women living with HIV. Cochrane Database Syst. Rev. CD007844.
44. Cerutti, A., Puga, I., and Cols, M. (2011). Innate control of B cell responses. Trends Immunol. 32, 202-211.
45. Chamberland, A., Diabate, S., Sylla, M., Anagounou, S., Geraldo, N., Zannou, D. M., Labbe, A. C., Worobey, M., Alary, M., and Tremblay, C. (2011). Transmission of HIV-1 drug resistance in Benin could jeopardise future treatment options. Sex Transm. Infect. 88, 179-183.
46. Chen, H., Xiang, Z. Q., Li, Y., Kurupati, R. K., Jia, B., Bian, A., Zhou, D. M., Hutnick, N., Yuan, S., Gray, C., Serwanga, J., Auma, B., Kaleebu, P., Zhou, X., Betts, M. R., and Ertl, H. C. (2010). Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J. Virol. 84, 10522-10532.
47. Chen, W., Streaker, E. D., Russ, D. E., Feng, Y., Prabakaran, P., and Dimitrov, D. S. (2012). Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: implications for mechanisms of immune evasion and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 417, 1164-1169.
48. Chesson, H. W., Gift, T. L., Owusu-Edusei, K. Jr., Tao, G., Johnson, A. P., and Kent, C. K. (2011). A brief review of the estimated economic burden of sexually transmitted diseases in the United States: inflation-adjusted updates of previously published cost studies. Sex Tr a n s m. D i s. 38, 889-891.
49. Chong, Y., Ikematsu, H., Kikuchi, K., Yamamoto, M., Murata, M., Nishimura, M., Nabeshima, S., Kashiwagi, S., and Hayashi, J. (2004). Selective CD27+ (memory) B cell reduction and characteristic B cell alteration in drug-naive and HAART-treated HIV type 1-infected patients. AIDS Res. Hum. Retroviruses 20, 219-226.
50. Christensen, D., Korsholm, K. S., Andersen, P., and Agger, E. M. (2011). Cationic liposomes as vaccine adjuvants. Expert Rev. Vaccines 10, 513-521.
51. Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., Godbole, S. V., Mehendale, S., Chariyalertsak, S., Santos, B. R., Mayer, K. H., Hoffman, I. F., Eshleman, S. H., Piwowar-Manning, E., Wang, L., Makhema, J., Mills, L. A., de Bruyn, G., Sanne, I., Eron, J., Gallant, J., Havlir, D., Swindells, S., Ribaudo, H., Elharrar, V., Burns, D., Taha, T. E., Nielsen-Saines, K., Celentano, D., Essex, M., and Fleming, T. R., for the HPTN 052 Study Team. (2011). Prevention of HIV-1 infection with early antiretroviral therapy. N. Eng. J. Med. 365, 493-505.
52. Collins-Fairclough, A. M., Charurat, M., Nadai, Y., Pando, M., Avila, M. M., Blattner, W. A., and Carr, J. K. (2011). Significantly longer envelope V2 loops are characteristic of heterosexually transmitted subtype B HIV-1 in Trinidad. PLoS ONE 6:e19995. doi: 10.1371/journal.pone.0019995
53. Colombo, G. L., Colangeli, V., Di Biagio, A., Di Matteo, S., Viscoli, C., and Viale, P. (2011). Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. Clinicoecon Outcomes Res. 3, 197-205.
54. Dahl, V., Lee, E., Peterson, J., Spudich, S. S., Leppla, I., Sinclair, E., Fuchs, D., Palmer, S., and Price, R. W. (2011). Raltegravir treatment intensification does not alter cere-brospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J. Infect. Dis. 204, 1936-1945.
55. Dang, B. N., Giordano, T. P., and Kim, J. H. (2011). Sociocultural and structural barriers to care among undocumented Latino immigrants with HIV infection. J. Immigr. Minor. Health 14, 124-131.
56. Demarest, J. F., Amrine-Madsen, H., Irlbeck, D. M., and Kitrinos, K. M. (2009). Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism. Antimicrob. Agents Chemother. 53, 1116-1123.
57. Demberg, T., Boyer, J. D., Malkevich, N., Patterson, L. J., Venzon, D., Summers, E. L., Kalisz, I., Kalyanaraman, V. S., Lee, E. M., Weiner, D. B., and Robert-Guroff, M. (2008). Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recom-binant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge. J. Virol. 82, 10911-10921.
58. Demberg, T., and Robert-Guroff, M. (2009). Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int. Rev. Immunol. 28, 20-48.
59. Denton, P. W., Othieno, F., Martinez-Torres, F., Zou, W., Krisko, J. F., Fleming, E., Zein, S., Powell, D. A., Wahl, A., Kwak, Y. T., Welch, B. D., Kay, M. S., Payne, D. A., Gallay, P., Appella, E., Estes, J. D., Lu, M., and Garcia, J. V. (2011). One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J. Virol. 85, 7582-7593.
60. D'Ettorre, G., Paiardini, M., Ceccarelli, G., Silvestri, G., and Vullo, V. (2011). HIV-associated immune activation: from bench to bedside. AIDS Res. Hum. Retroviruses 27, 355-364.
61. DeVico, A., Fouts, T., Lewis, G. K., Gallo, R. C., Godfrey, K., Charurat, M., Harris, I., Galmin, L., and Pal, R. (2007). Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc. Natl. Acad. Sci. U.S.A. 104, 17477-17482.
62. Dolling, D., Phillips, A., Delpech, V., Pillay, D., Cane, P., Crook, A., Shepherd, J., Fearnhill, E., Hill, T., Dunn, D., On Behalf of The UK HIV Drug Resistance Database, and The UK Collaborative HIV Cohort (UK CHIC) Study. (2011). Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. HIV Med. 13, 309-314.
63. Doores, K. J., and Burton, D. R. (2010). Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J. Virol. 84, 10510-10521.
64. Duthie, M. S., Windish, H. P., Fox, C. B., and Reed, S. G. (2011). Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev. 239, 178-196.
65. East, L., Jackson, D., O'Brien, L., and Peters, K. (2011). Condom negotiation: experiences of sexually active young women. J. Adv. Nurs. 67, 77-85.
66. El-Bassel, N., Gilbert, L., Witte, S., Wu, E., and Chang, M. (2011). Intimate partner violence and HIV among drug-involved women: contexts linking these two epidemics-challenges and implications for prevention and treatment. Subst. Use Misuse 46, 295-306.
67. Epeldegui, M., Vendrame, E., and Martinez-Maza, O. (2010). HIV-associated immune dysfunction and viral infection: role in the patho-genesis of AIDS-related lymphoma. Immunol. Res. 48, 72-83.
68. Espinoza, L., Hall, H. I., and Hu, X. (2012). Diagnoses of HIV Infection among Hispanics/Latinos in 40 States and Puerto Rico, 2006-2009. J. Acquir. Immune. Defic. Syndr. 60, 205-213.
69. Euler, Z., van den Kerkhof, T. L., van Gils, M. J., Burger, J. A., Edo-Matas, D., Phung, P., Wrin, T., and Schuitemaker, H. (2012). Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity. J. Virol. 86, 2045-2055.
70. Fair, C. D., and Vanyur, J. (2011). Sexual coercion, verbal aggression, and condom use consistency among college students. J. Am. Coll. Health 59, 273-280.
71. Fernando, K., Hu, H., Ni, H., Hoxie, J. A., and Weissman, D. (2007). Vaccine-delivered HIV envelope inhibits CD4(+) T-cell activation, a mechanism for poor HIV vaccine responses. Blood 109, 2538-2544.
72. Fernandez-Montero, J. V., Barreiro, P., Del Romero, J., and Soriano, V. (2012). Antiretroviral drugs for pre-exposure prophylaxis of HIV infection. AIDS Rev. 14, 54-61.
73. Ferraro, B., Morrow, M. P., Hutnick, N. A., Shin, T. H., Lucke, C. E., and Weiner, D. B. (2011). Clinical applications of DNA vaccines: current progress. Clin. Infect. Dis. 53, 296-302.
74. Fichtenbaum, C. J. (2010). Does antiretroviral therapy increase or decrease the risk of cardiovascular disease? Curr. HIV/AIDS Rep. 7, 92-98.
75. Finlayson, T. J., Le, B., Smith, A., Bowles, K., Cribbin, M., Miles, I., Oster, A. M., Martin, T., Edwards, A., and Dinenno, E. (2011). HIV risk, prevention, and testing behaviors among men who have sex with men-National HIV Behavioral Surveillance System, 21 U.S. cities, United States, 2008. MMWR Surveill. Summ. 60, 1-34.
76. Fleishman, J. A., Yehia, B. R., Moore, R. D., and Gebo, K. A. (2010). The economic burden of late entry into medical care for patients with HIV infection. Med. Care 48, 1071-1079.
77. Flynn, N. M., Forthal, D. N., Harro, C. D., Judson, F. N., Mayer, K. H., and Para, M. F. (2005). Placebo-controlled phase 3 trial of a recom-binant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191, 654-665.
78. Franchini, G., Gurunathan, S., Baglyos, L., Plotkin, S., and Tartaglia, J. (2004). Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert. Rev. Vaccines 3, S75-88.
79. Frater, J. (2011). New approaches in HIV eradication research. Curr. Opin. Infect. Dis. 24, 593-598.
80. Furlan, A., Monzani, V., Reznikov, L. L., Leoni, F., Fossati, G., Modena, D., Mascagni, P., and Dinarello, C. A. (2011). Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral his-tone deacetylase inhibitor ITF2357 (givinostat). Mol. Med. 17, 353-362.
81. Gakumo, C. A., Moneyham, L. D., Enah, C. C., and Childs, G. D. (2011). The moderating effect of sexual pressure on young Urban women's condom use. Res. Nurs. Health 35, 4-14.
82. García, F., Climent, N., Assoumou, L., Gil, C., González, N., Alcamí, J., León, A., Romeu, J., Dalmau, J., Martínez-Picado, J., Lifson, J., Autran, B., Costagliola, D., Clotet, B., Gatell, J. M., Plana, M., Gallart, T., and DCV2/MANON07-AIDS Vaccine Research Objective Study Group. (2011). A therapeutic dendritic cell-based vaccine for HIV-1 infection. J. Infect. Dis. 203, 473-478.
83. Gebo, K. A., Fleishman, J. A., Conviser, R., Hellinger, J., Hellinger, F. J., Josephs, J. S., Keiser, P., Gaist, P., and Moore, R. D. (2010). Contemporary costs of HIV healthcare in the HAART era. AIDS 24, 2705-2715.
84. Gebremedhin, S. (2010). Assessment of the protective effect of male circumcision from HIV infection and sexually transmitted diseases: evidence from 18 demographic and health surveys in sub-Saharan Africa. Afr. J. Reprod. Health 14, 105-113.
85. Gervaz, P., Calmy, A., Durmishi, Y., Allal, A. S., and Morel, P. (2011). Squamous cell carcinoma of the anus-an opportunistic cancer in HIV-positive male homosexuals. World J. Gastroenterol. 17, 2987-2991.
86. Girard, M. P., Osmanov, S., Assossou, O. M., and Kieny, M. P. (2011). Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Va c c i n e 29, 6191-6218.
87. Golub, S. A., Kowalczyk, W., Weinberger, C. L., and Parsons, J. T. (2010). Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J. Acquir. Immune. Defic. Syndr. 54, 548-555.
88. Gomez, C. E., Najera, J. L., Krupa, M., and Esteban, M. (2008). The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr. Gene Ther. 8, 97-120.
89. Gonzalez-Martin, A., Gomez, L., Lustgarten, J., Mira, E., and Manes, S. (2011). Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res. 71, 5455-5466.
90. Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapia, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., Montoya-Herrera, O., Fernandez, T., Veloso, V. G., Buchbinder, S. P., Chariyalertsak, S., Schechter, M., Bekker, L. G., Mayer, K. H., Kallas, E. G., Amico, K. R., Mulligan, K., Bushman, L. R., Hance, R. J., Ganoza, C., Defechereux, P., Postle, B., Wang, F., McConnell, J. J., Zheng, J. H., Lee, J., Rooney, J. F., Jaffe, H. S., Martinez, A. I., Burns, D. N., and Glidden, D. V. (2010). Preexposure chemopro-phylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363, 2587-2599.
91. Gray, G. E., Allen, M., Moodie, Z., Churchyard, G., Bekker, L. G., Nchabeleng, M., Mlisana, K., Metch, B., De Bruyn, G., Latka, M. H., Roux, S., Mathebula, M., Naicker, N., Ducar, C., Carter, D. K., Puren, A., Eaton, N., McElrath, M. J., Robertson, M., Corey, L., and Kublin, J. G. (2011). Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect. Dis. 11, 507-515.
92. Gray, R. H., Kigozi, G., Serwadda, D., Makumbi, F., Watya, S., Nalugoda, F., Kiwanuka, N., Moulton, L. H., Chaudhary, M. A., Chen, M. Z., Sewankambo, N. K., Wabwire-Mangen, F., Bacon, M. C., Williams, C. F., Opendi, P., Reynolds, S. J., Laeyendecker, O., Quinn, T. C., and Wawer, M. J. (2007). Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369, 657-666.
93. Greenberg, A. E., Hader, S. L., Masur, H., Young, A. T., Skillicorn, J., and Dieffenbach, C. W. (2009). Fighting HIV/AIDS in Washington, D.C. Health Aff. (Millwood) 28, 1677-1687.
94. Gudmundsdotter, L., Boström, A. C., Burton, C., Rosignoli, G., Sandström, E., Hejdeman, B., Wahren, B., Imami, N., and Gotch, F. (2008). Long-term increase of CD4+ central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunization. Va c c i n e 26, 5107-5110.
95. Gust, D. A., Wiegand, R. E., Kretsinger, K., Sansom, S., Kilmarx, P. H., Bartholow, B. N., and Chen, R. T. (2010). Circumcision status and HIV infection among MSM: reanal-ysis of a Phase III HIV vaccine clinical trial. AIDS 24, 1135-1143.
96. Hagger-Johnson, G., Bewick, B. M., Conner, M., O'Connor, D. B., and Shickle, D. (2011). Alcohol, conscientiousness and event-level condom use. Br. J. Health Psychol. 16, 828-845.
97. Hamilton, C. L., Eyzaguirre, L. M., Amarakoon, I. I., Figueroa, P., Duncan, J., Carr, J. K., and Roye, M. E. (2012). Analysis of protease and reverse transcriptase genes of HIV for antiretroviral drug resistance in Jamaican adults. AIDS Res. Hum. Retroviruses 28, 923-927.
98. Hanna, D. B., Selik, R. M., Tang, T., and Gange, S. J. (2011). Disparities among states in HIV-related mortality in persons with hiv infection, 37 US States, 2001-2007. AIDS 6, 95-103.
99. Hansen, S. G., Ford, J. C., Lewis, M. S., Ventura, A. B., Hughes, C. M., Coyne-Johnson, L., Whizin, N., Oswald, K., Shoemaker, R., Swanson, T., Legasse, A. W., Chiuchiolo, M. J., Parks, C. L., Axthelm, M. K., Nelson, J. A., Jarvis, M. A., Piatak, M. Jr., Lifson, J. D., and Picker, L. J. (2011). Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523-527.
100. Harris, A., Borgnia, M. J., Shi, D., Bartesaghi, A., He, H., Pejchal, R., Kang, Y. K., Depetris, R., Marozsan, A J., Sanders, R. W., Klasse, P. J., Milne, J. L., Wilson, I. A., Olson, W. C., Moore, J. P., and Subramaniam, S. (2011). Trimeric HIV-1 glycopro-tein gp140 immunogens and native HIV-1 envelope glycoproteins dis play the same closed and open quaternary molecular architectures. Proc. Natl. Acad. Sci. U.S.A. 108, 11440-11445.
101. Haynes, B. F., Fleming, J., St Clair, E. W., Katinger, H., Stiegler, G., Kuner, R., Robinson, J., Plonk, K., Staats, H. F., Ortel, T. L., Liao, H. X., and Alam, S. M. (2005). Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308, 1906-1908.
102. Herbst-Kralovetz, M., Mason, H. S., and Chen, Q. (2010). Norwalk virus-like particles as vaccines. Expert Rev. Vaccines 9, 299-307.
103. Hill, A. M., Cho, M., and Mrus, J. M. (2011). The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients. AIDS Rev. 13, 41-48.
104. Hsu, J., Zinsou, C., Parkhurst, J., N'Dour, M., Foyet, L., and Mueller, D. H. (2012). Comparative costs and cost-effectiveness of behavioural interventions as part of HIV prevention strategies. Health Policy Plan. doi: 10.1093/heapol/czs021. [Epub ahead of print].
105. Hudgens, M. G., and Gilbert, P. B. (2009). Assessing vaccine effects in repeated low-dose challenge experiments. Biometrics 65, 1223-1232.
106. Iglesias-Ussel, M. D., and Romerio, F. (2011). HIV reservoirs: the new frontier. AIDS Rev. 13, 13-29.
107. Islam, F. M., Wu, J., Jansson, J., and Wilson, D. (2012a). Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med.
108. Islam, F. M., Wu, J., Jansson, J., and Wilson, D. P. (2012b). Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis. BMC Public Health 12, 234.
109. Jewkes, R. K., Dunkle, K., Nduna, M., and Shai, N. (2010). Intimate partner violence, relationship power inequity, and incidence of HIV infection in young women in South Africa: a cohort study. Lancet 376, 41-48.
110. Jiang, X., Burke, V., Totrov, M., Williams, C., Cardozo, T., Gorny, M. K., Zolla-Pazner, S., and Kong, X. P. (2010). Conserved structural elements in the V3 crown of HIV-1 gp120. Nat. Struct. Mol. Biol. 17, 955-961.
111. Jin, X., Ramanathan, M. Jr., Barsoum, S., Deschenes, G. R., Ba, L., Binley, J., Schiller, D., Bauer, D. E., Chen, D. C., Hurley, A., Gebuhrer, L., El Habib, R., Caudrelier, P., Klein, M., Zhang, L., Ho, D. D., and Markowitz, M. (2002). Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J. Virol. 76, 2206-2216.
112. Johnson, P. R., Schnepp, B. C., Zhang, J., Connell, M. J., Greene, S. M., Yuste, E., Desrosiers, R. C., and Clark, K. R. (2009). Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat. Med. 15, 901-906.
113. Jozkowski, K., Rosenberger, J. G., Schick, V., Herbenick, D., Novak, D. S., and Reece, M. (2010). Relations between circumcision status, sexually transmitted infection history, and HIV serostatus among a national sample of men who have sex with men in the United States. AIDS Patient Care STDS 24, 465-470.
114. Kalyesubula, R., and Perazella, M. A. (2011). Nephrotoxicity of HAART. AIDS Res. Treat. 2011, 562790.
115. Keele, B. F., Li, H., Learn, G. H., Hraber, P., Giorgi, E. E., Grayson, T., Sun, C., Chen, Y., Yeh, W. W., Letvin, N. L., Mascola, J. R., Nabel, G. J., Haynes, B. F., Bhattacharya, T., Perelson, A. S., Korber, B. T., Hahn, B. H., and Shaw, G. M. (2009). Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J. Exp. Med. 206, 1117-1134.
116. Keiser, O., Chi, B. H., Gsponer, T., Boulle, A., Orrell, C., Phiri, S., Maxwell, N., Maskew, M., Prozesky, H., Fox, M. P., Westfall, A., Egger, M., and IeDEA Southern Africa Collaboration. (2011). Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. AIDS 25, 1761-1769.
117. Kelly, J. A., Amirkhanian, Y. A., Kabakchieva, E., Vassileva, S., Vassilev, B., McAuliffe, T. L., Difranceisco, W. J., Antonova, R., Petrova, E., Khoursine, R. A., and Dimitrov, B. (2006). Prevention of HIV and sexually transmitted diseases in high risk social networks of young Roma (Gypsy) men in Bulgaria: randomised controlled trial. BMJ 333, 1098.
118. Kim, S. S., Peer, D., Kumar, P., Subramanya, S., Wu, H., Asthana, D., Habiro, K., Yang, Y. G., Manjunath, N., Shimaoka, M., and Shankar, P. (2010). RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol. Ther. 18, 370-376.
119. Kindberg, E., Mickiene, A., Ax, C., Akerlind, B., Vene, S., Lindquist, L., Lundkvist, A., and Svensson, L. (2008). A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J. Infect. Dis. 197, 266-269.
120. Kitrinos, K. M., Amrine-Madsen, H., Irlbeck, D. M., Word, J. M., and Demarest, J. F. (2009). Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope. Antimicrob. Agents Chemother. 53, 1124-1131.
121. Koblin, B., Chesney, M., and Coates, T. (2004). Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet 364, 41-50.
122. Kogan, S. M., Brody, G. H., Chen, Y. F., Grange, C. M., Slater, L. M., and Diclemente, R. J. (2010). Risk and protective factors for unprotected intercourse among rural African American young adults. Public Health Rep. 125, 709-717.
123. Koppenhaver, R. T., Sorensen, S. W., Farnham, P. G., and Sansom, S. L. (2011). The cost-effectiveness of pre-exposure prophylaxis in men who have sex with men in the United States: an epidemic model. J. Acquir. Immune. Defic. Syndr. 58, e51-e 52.
124. Krakower, D., and Mayer, K. H. (2011). Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications. Curr. HIV/AIDS Rep. 8, 241-248.
125. Krentz, H. B., and Gill, M. J. (2012). The direct medical costs of late presentation (<350/mm) of HIV infection over a 15-year period. AIDS Res. Treat. 2012, 757135.
126. Kundu-Raychaudhuri, S., Sevin, A., Kilgo, P., Nokta, M., Pollard, R. B., and Merigan, T. C. (2001). Effect of therapeutic immunization with HIV type 1 recombinant gly-coprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of>or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946). AIDS Res. Hum. Retroviruses 17, 1371-1378.
127. Kumar, R., Tuen, M., Li, H., Tse, D. B., and Hioe, C. E. (2011). Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation. Va c c i n e 29, 9064-9074.
128. Kwong, P. D., Mascola, J. R., and Nabel, G. J. (2011). Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb. Perspect. Med. 1, a007278.
129. Lafeuillade, A., and Stevenson, M. (2011). The search for a cure for persistent HIV reservoirs. AIDS Rev. 13, 63-66.
130. Lagenaur, L. A., Sanders-Beer, B. E., Brichacek, B., Pal, R., Liu, X., Liu, Y., Yu, R., Venzon, D., Lee, P. P., and Hamer, D. H. (2011). Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol. 4, 648-657.
131. Lai, L., Kwa, S., Kozlowski, P. A., Montefiori, D. C., Ferrari, G., Johnson, W. E., Hirsch, V., Villinger, F., Chennareddi, L., Earl, P. L., Moss, B., Amara, R. R., and Robinson, H. L. (2011). Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J. Infect. Dis. 204, 164-173.
132. Lehrman, G., Hogue, I. B., Palmer, S., Jennings, C., Spina, C. A., Wiegand, A., Landay, A. L., Coombs, R. W., Richman, D. D., Mellors, J. W., Coffin, J. M., Bosch, R. J., and Margolis, D. M. (2005). Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366, 549-555.
133. Leibowitz, A. A., Parker, K. B., and Rotheram-Borus, M. J. (2011). A US policy perspective on oral preex-posure prophylaxis for HIV. Am. J. Public Health 101, 982-985.
134. Lewis, D. J., Fraser, C. A., Mahmoud, A. N., Wiggins, R. C., Woodrow, M., Cope, A., Cai, C., Giemza, R., Jeffs, S. A., Manoussaka, M., Cole, T., Cranage, M. P., Shattock, R. J., and Lacey, C. J. (2011). Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally. PLoS ONE 6:e25165. doi: 10.1371/journal.pone.0025165
135. Li, J. Z., Brumme, Z. L., Brumme, C. J., Wang, H., Spritzler, J., Robertson, M. N., Lederman, M. M., Carrington, M., Walker, B. D., Schooley, R. T., Kuritzkes, D. R., and AIDS Clinical Trials Group A5197 Study Team. (2011). Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. J. Infect. Dis. 203, 976-983.
136. Lim, J. K., McDermott, D. H., Lisco, A., Foster, G. A., Krysztof, D., Follmann, D., Stramer, S. L., and Murphy, P. M. (2010). CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J. Infect. Dis. 201, 178-185.
137. Llibre, J. M., Falco, V., Tural, C., Negredo, E., Pineda, J. A., Munoz, J., Ortega, E., Videla, S., Sirera, G., Martinez, E., Miralles, C., Iribarren, J., Galindo, M. J., Domingo, P., D'Arminio-Monforte, A., Miro, J. M., and Clotet, B. (2009). The changing face of HIV/AIDS in treated patients. Curr. HIV Res. 7, 365-377.
138. Long, E. F., and Owens, D. K. (2011). The cost-effectiveness of a modestly effective HIV vaccine in the United States. Va c c i n e 29, 6113-6124.
139. Lovgren Bengtsson, K., Morein, B., and Osterhaus, A. D. (2011). ISCOM technology-based Matrix M adjuvant: success in future vaccines relies on formulation. Expert Rev. Vaccines 10, 401-403.
140. Maggi, P., Bartolozzi, D., Bonfanti, P., Calza, L., Cherubini, C., Di Biagio, A., Marcotullio, S., Montella, F., Montinaro, V., Mussini, C., Narciso, P., Rusconi, S., and Vescini, F. (2012). Renal complications in HIV disease: between present and future. AIDS Rev. 14, 37-53.
141. Maisto, S. A., Palfai, T., Vanable, P. A., Heath, J., and Woolf-King, S. E. (2012). The effects of alcohol and sexual arousal on determinants of sexual risk in men who have sex with men. Arch. Sex Behav. 41, 971-986.
142. Manrique, M., Kozlowski, P. A., Cobo-Molinos, A., Wang, S. W., Wilson, R. L., Montefiori, D. C., Mansfield, K. G., Carville, A., and Aldovini, A. (2011). Long-term control of simian immunodeficiency virus mac251 viremia to undetectable levels in half of infected female rhesus macaques nasally vaccinated with simian immunodeficiency virus DNA/recombinant modified vaccinia virus Ankara. J. Immunol. 186, 3581-3593.
143. Margolis, D. M. (2011). Histone deacetylase inhibitors and HIV latency. Curr. Opin. HIV AIDS 6, 25-29.
144. Marsden, M. D., Kovochich, M., Suree, N., Shimizu, S., Mehta, R., Cortado, R., Bristol, G., An, D. S., and Zack, J. A. (2011). HIV latency in the humanized BLT mouse. J. Virol. 86, 339-347.
145. Mascola, J. R., Stiegler, G., Vancott, T. C., Katinger, H., Carpenter, C. B., Hanson, C. E., Beary, H., Hayes, D., Frankel, S. S., Birx, D. L., and Lewis, M. G. (2000).Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6, 207-210.
146. Matalon, S., Rasmussen, T. A., and Dinarello, C. A. (2011). Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol. Med. 17, 466-472.
147. McCarty, E. J., Quah, S., Maw, R., Dinsmore, W. W., and Emerson, C. R. (2011). Post-exposure prophylaxis following sexual exposure to HIV: a seven-year retrospective analysis in a regional centre. Int. J. STD AIDS 22, 407-408.
148. McCormack, S., Ramjee, G., Kamali, A., Rees, H., Crook, A. M., Gafos, M., Jentsch, U., Pool, R., Chisembele, M., Kapiga, S., Mutemwa, R., Vallely, A., Palanee, T., Sookrajh, Y., Lacey, C. J., Darbyshire, J., Grosskurth, H., Profy, A., Nunn, A., Hayes, R., and Weber, J. (2010). PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 376, 1329-1337.
149. Mestecky, J., Raska, M., Novak, J., Alexander, R. C., and Moldoveanu, Z. (2010). Antibody-mediated protection and the mucosal immune system of the genital tract: relevance to vaccine design. J. Reprod. Immunol. 85, 81-85.
150. Moir, S., and Fauci, A. S. (2009). B cells in HIV infection and disease. Nat. Rev. Immunol. 9, 235-245.
151. Moore, R. D. (2011). Epidemiology of HIV infection in the United States: implications for linkage to care. Clin. Infect. Dis. 52, S208-S213.
152. Morgan, C., Marthas, M., Miller, C., Duerr, A., Cheng-Mayer, C., Desrosiers, R., Flores, J., Haigwood, N., Hu, S. L., Johnson, R. P., Lifson, J., Montefiori, D., Moore, J., Robert-Guroff, M., Robinson, H., Self, S., and Corey, L. (2008). The use of nonhuman primate models in HIV vaccine development. PLoS Med. 5:e173. doi: 10.1371/journal.pmed.0050173
153. Morris, S. R., and Little, S. J. (2011). MSM: resurgent epidemics. Curr. Opin. HIV AIDS 6, 326-332.
154. Muster, T., Steindl, F., Purtscher, M., Trkola, A., Klima, A., Himmler, G., Rüker, F., and Katinger, H. (1993). A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67, 6642-6647.
155. Myers, G. M., and Mayer, K. H. (2011). Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS 25, 63-71.
156. Nacopoulos, A. G., Lewtas, A. J., and Ousterhout, M. M. (2010). Syringe exchange programs: impact on injection drug users and the role of the pharmacist from a U.S. perspective. J. Am. Pharm. Assoc. (2003) 50, 148-157.
157. Naswa, S., and Marfatia, Y. S. (2011). Pre-exposure prophylaxis of HIV. Indian J. Sex Transm. Dis. 32, 1-8.
158. Negri, D. R., Michelini, Z., Bona, R., Blasi, M., Filati, P., Leone, P., Rossi, A., Franco, M., and Cara, A. (2011). Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity. Expert Opin. Biol. Ther. 11, 739-750.
159. Neuhaus, J., Jacobs, D. R., Jr., Baker, J. V., Calmy, A., Duprez, D., La Rosa, A., Kuller, L. H., Pett, S. L., Ristola, M., Ross, M. J., Shlipak, M. G., Tracy, R., and Neaton, J. D. (2011). Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J. Infect. Dis. 201, 1788-1795.
160. Nichols, W. G., Steel, H. M., Bonny, T., Adkison, K., Curtis, L., Millard, J., Kabeya, K., and Clumeck, N. (2008). Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob. Agents Chemother. 52, 858-865.
161. Nishimura, Y., Igarashi, T., Haigwood, N. L., Sadjadpour, R., Donau, O. K., Buckler, C., Plishka, R. J., Buckler-White, A., and Martin, M. A. (2003). Transfer of neutralizing IgG to macaques 6h but not 24h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc. Natl. Acad. Sci. U.S.A. 100, 15131-15136.
162. Nunn, A. S., Fonseca, E. M., Bastos, F. I., Gruskin, S., and Salomon, J. A. (2007). Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment. PLoS Med. 4:e305. doi: 10.1371/journal.pmed.0040305
163. Obiako, O. R., and Muktar, H. M. (2010). Challenges of HIV treatment in resource-poor countries: a review. Niger. J. Med. 19, 361-368.
164. Ogert, R. A., Wojcik, L., Buontempo, C., Ba, L., Buontempo, P., Ralston, R., Strizki, J., and Howe, J. A. (2008). Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 373, 387-399.
165. O'Hagan, D. T., Rappuoli, R., De Gregorio, E., Tsai, T., and Del Giudice, G. (2011). MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev. Vaccines 10, 447-462.
166. Ojo, O., Verbeek, J. H., Rasanen, K., Heikkinen, J., Isotalo, L. K., Mngoma, N., and Ruotsalainen, E. (2011). Interventions to reduce risky sexual behaviour for preventing HIV infection in workers in occupational settings. Cochrane Database Syst. Rev. CD005274.
167. Olesen, R., Wahl, A., Denton, P. W., and Garcia, J. V. (2011). Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection. J. Reprod. Immunol. 88, 195-203.
168. Olive, A. J., Gondek, D. C., and Starnbach, M. N. (2011). CXCR3 and CCR5 are both required for T cell-mediated protection against C. trachomatis infection in the murine genital mucosa. Mucosal Immunol. 4, 208-216.
169. Owoaje, E. T., Adebiyi, A. O., and Adebayo, M. A. (2011). Sexual risk behaviours and HIV knowledge of migrant farm workers in a rural community in Nigeria. Afr. J. Med. Med. Sci. 40, 75-84.
170. Oyewumi, M. O., Kumar, A., and Cui, Z. (2010). Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev. Vaccines9, 1095-1107.
171. Pace, M. J., Agosto, L., Graf, E. H., and O'Doherty, U. (2011). HIV reservoirs and latency models. Virology 411, 344-354.
172. Padte, N. N., Li, X., Tsuji, M., and Vasan, S. (2011). Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clin. Immunol. 140, 142-151.
173. Palmer, S., Josefsson, L., and Coffin, J. M. (2011). HIV reservoirs and the possibility of a cure for HIV infection. J. Intern. Med. 270, 550-560.
174. Palucka, K., Banchereau, J., and Mellman, I. (2010). Designing vaccines based on biology of human dendritic cell subsets. Immunity 33, 464-478.
175. Patel, V., Valentin, A., Kulkarni, V., Rosati, M., Bergamaschi, C., Jalah, R., Alicea, C., Minang, J. T., Trivett, M. T., Ohlen, C., Zhao, J., Robert-Guroff, M., Khan, A. S., Draghia-Akli, R., Felber, B. K., and Pavlakis, G. N. (2010). Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Va c c i n e 28, 4827-4836.
176. Patterson, L. J., and Robert-Guroff, M. (2008). Replicating aden-ovirus vector prime/protein boost strategies for HIV vaccine development. Expert Opin. Biol. Ther. 8, 1347-1363.
177. Patterson, L. J., Kuate, S., Daltabuit-Test, M., Li, Q., Xiao, P., McKinnon, K., DiPasquale, J., Cristillo, A., Venzon, D., Haase, A., and Robert-Guroff, M. (2012). Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route. Clin. Vaccine Immunol. 19, 629-637.
178. Pejchal, R., Doores, K. J., Walker, L. M., Khayat, R., Huang, P. S., Wang, S. K., Stanfield, R. L., Julien, J. P., Ramos, A., Crispin, M., Depetris, R., Katpally, U., Marozsan, A., Cupo, A., Maloveste, S., Liu, Y., McBride, R., Ito, Y., Sanders, R. W., Ogohara, C., Paulson, J. C., Feizi, T., Scanlan, C.N., Wong, C. H., Moore, J. P., Olson, W. C., Ward, A. B., Poignard, P., Schief, W. R., Burton, D.R., and Wilson, I. A. (2011). A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334, 1097-1103.
179. Pejchal, R., and Wilson, I. A. (2010). Structure-based vaccine design in HIV: blind men and the elephant? Curr. Pharm. Des. 16, 3744-3753.
180. Perrin, H., Canderan, G., Sekaly, R. P., and Trautmann, L. (2010). New approaches to design HIV-1 T-cell vaccines. Curr. Opin. HIV AIDS 5, 368-376.
181. Petrovsky, N., and Cooper, P. D. (2011). Carbohydrate-basedimmune adjuvants. Expert Rev. Vaccines 10, 523-537.
182. Pirrone, V., Passic, S., Wigdahl, B., and Krebs, F. C. (2012). Application and removal of polyanionic micro-bicide compounds enhances subsequent infection by HIV-1. Virol. J. 9, 33.
183. Pirrone, V., Wigdahl, B., and Krebs, F. C. (2011). The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antiviral. Res. 90, 168-182.
184. Pitisuttithum, P., Gilbert, P., Gurwith, M., Heyward, W., Martin, M., Van Griensven, F., Hu, D., Tappero, J. W., and Choopanya, K. (2006). Randomized,double-blind, placebo-controlled efficacy trial of a bivalent recombinant glyco-protein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194, 1661-1671.
185. Prejean, J., Song, R., Hernandez, A., Ziebell, R., Green, T., Walker, F., Lin, L. S., An, Q., Mermin, J., Lansky, A., and Hall, H. I. (2011). Estimated HIV incidence in the United States, 2006-2009. PLoS ONE 6:e17502. doi: 10.1371/journal.pone.0017502
186. Price, C. F., Tyssen, D., Sonza, S., Davie, A., Evans, S., Lewis, G. R., Xia, S., Spelman, T., Hodsman, P., Moench, T. R., Humberstone, A., Paull, J. R., and Tachedjian, G. (2011). SPL7013 Gel (VivaGel(R)) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS ONE 6:e24095. doi: 10.1371/journal.pone.0024095
187. Pulendran, B., and Ahmed, R. (2011). Immunological mechanisms of vaccination. Nat. Immunol. 12, 509-517.
188. Putcharoen, O., Lee, S. H., Henrich, T. J., Hu, Z., Vanichanan, J., Coakley, E., Greaves, W., Gulick, R. M., Kuritzkes, D. R., and Tsibris, A. M. (2011). HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that correct in the presence of drug. J. Virol. 86, 1119-1128.
189. Ragupathi, G., Gardner, J. R., Livingston, P. O., and Gin, D. Y. (2011). Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Expert Rev. Vaccines 10, 463-470.
190. Reed, S. G., Bertholet, S., Coler, R. N., and Friede, M. (2009). New horizons in adjuvants for vaccine development. Trends Immunol. 30, 23-32.
191. Rehm, J., Shield, K. D., Joharchi, N., and Shuper, P. A. (2012). Alcohol consumption and the intention to engage in unprotected sex: systematic review and meta-analysis of experimental studies. Addiction 107, 51-59.
192. Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., De Souza, M., Adams, E., Benenson, M., Gurunathan, S., Tartaglia, J., McNeil, J. G., Francis, D. P., Stablein, D., Birx, D. L., Chunsuttiwat, S., Khamboonruang, C., Thongcharoen, P., Robb, M. L., Michael, N. L., Kunasol, P., and Kim, J. H. (2009). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220.
193. Resch, S., Korenromp, E., Stover, J., Blakley, M., Krubiner, C., Thorien, K., Hecht, R., and Atun, R. (2011). Economic returns to investment in AIDS treatment in low and middle income countries. PLoS ONE 6:e25310. doi: 10.1371/journal. pone.0025310
194. Rollier, C. S., Reyes-Sandoval, A., Cottingham, M. G., Ewer, K., and Hill, A. V. (2011). Viral vectors as vaccine platforms: deployment in sight. Curr. Opin. Immunol. 23, 377-382.
195. Rompay, K. K. (2011). The use of nonhuman primate models of HIV infection for the evaluation of antiviral strategies. AIDS Res. Hum. Retroviruses 28, 16-35.
196. Rotheram-Borus, M. J., Wu, Z., Liang, L. J., Li, L., Detels, R., Guan, J., Yin, Y., and Swendeman, D. (2011). Reductions in sexually transmitted infections associated with popular opinion leaders in China in a randomised controlled trial. Sex Transm. Infect. 87, 337-343.
197. Routy, J., Tremblay, C., Angel, J., Trottier, B., Rouleau, D., Baril, J., Harris, M., Trottier, S., Singer, J., Chomont, N., Sekaly, R., and Boulassel, M. (2012). Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med. 13, 291-296.
198. Roux, K. H., and Taylor, K. A. (2007). AIDS virus envelope spike structure. Curr. Opin. Struct. Biol. 17, 244-252.
199. Ryan, C. T. (2005). Trials of aplaviroc halted in treatment-naive patients. AIDS Clin. Care 17, 107-108.
200. Sagar, M., Wu, X., Lee, S., and Overbaugh, J. (2006). Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 80, 9586-9598.
201. Santos, S. P., Amado, C. A., and Santos, M. F. (2012). Assessing the efficiency of mother-to-child HIV prevention in low-and middle-income countries using data envelopment analysis. Health Care Manag. Sci. 15, 206-222.
202. Sardesai, N. Y., and Weiner, D. B. (2011). Electroporation delivery of DNA vaccines: prospects for success. Curr. Opin. Immunol. 23, 421-429.
203. Sax, P. E. (2006). Report from the 13th retrovirus conference. Vicriviroc less effective than efavirenz in treatment-naive patients. AIDS Clin. Care 18, 34-35.
204. Scheid, J. F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T. Y., Pietzsch, J., Fenyo, D., Abadir, A., Velinzon, K., Hurley, A., Myung, S., Boulad, F., Poignard, P., Burton, D. R., Pereyra, F., Ho, D. D., Walker, B. D., Seaman, M. S., Bjorkman, P. J., Chait, B. T., and Nussenzweig, M. C. (2011). Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-1637.
205. Schief, W. R., Ban, Y. E., and Stamatatos, L. (2009). Challenges for structure-based HIV vaccine design. Curr. Opin. HIV AIDS 4, 431-440.
206. Schijns, V. E., and Lavelle, E. C. (2011). Trends in vaccine adjuvants. Expert Rev. Vaccines 10, 539-550.
207. Schneider, K., Kerr, C. C., Hoare, A., and Wilson, D. P. (2011). Expected epidemiological impacts of introducing an HIV vaccine in thailand: a model-based analysis. Vaccine 29, 6086-6091.
208. Selhorst, P., Grupping, K., Bourlet, T., Delezay, O., Arien, K. K., and Vanham, G. (2011). In vitro activity of candidate microbicides against cell-associated Hiv. Antimicrob. Agents Chemother. 56, 805-815.
209. Sellar, R. S., and Peggs, K. S. (2012). Therapeutic strategies for the prevention and treatment of cytomegalovirus infection. Expert Opin. Biol. Ther. doi: 10.1517/ 14712598.2012.693471.[Epub ahead of print].
210. Sellhorn, G., Kraft, Z., Caldwell, Z., Ellingson, K., Mineart, C., Seaman, M. S., Montefiori, D. C., Lagerquist, E., and Stamatatos, L. (2011). Engineering, expression, purification and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins. J. Virol. 86, 128-142.
211. Shahabi, V., Maciag, P. C., Rivera, S., and Wallecha, A. (2010). Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment. Bioeng. Bugs 1, 235-243.
212. Shedlock, D. J., Silvestri, G., and Weiner, D. B. (2009). Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat. Rev. Immunol. 9, 717-728.
213. Shimizu, S., Hong, P., Arumugam, B., Pokomo, L., Boyer, J., Koizumi, N., Kittipongdaja, P., Chen, A., Bristol, G., Galic, Z., Zack, J. A., Yang, O., Chen, I. S., Lee, B., and An, D. S. (2010). A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood 115, 1534-1544.
214. Siegfried, N., Muller, M., Deeks, J. J., and Volmink, J. (2009). Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst. Rev. CD003362.
215. Siegfried, N., van der Merwe, L., Brocklehurst, P., and Sint, T. T. (2011). Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst. Rev. CD003510.
216. Sigal, A., Kim, J. T., Balazs, A. B., Dekel, E., Mayo, A., Milo, R., and Baltimore, D. (2011). Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477, 95-98.
217. Sigaloff, K. C., Calis, J. C., Geelen, S. P., Van Vugt, M., and De Wit, T. F. (2011). HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. Lancet Infect. Dis. 11, 769-779.
218. Skoler-Karpoff, S., Ramjee, G., Ahmed, K., Altini, L., Plagianos, M. G., Friedland, B., Govender, S., De Kock, A., Cassim, N., Palanee, T., Dozier, G., Maguire, R., and Lahteenmaki, P. (2008). Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372, 1977-1987.
219. Smith, D. K., Taylor, A., Kilmarx, P. H., Sullivan, P., Warner, L., Kamb, M., Bock, N., Kohmescher, B., and Mastro, T. D. (2010). Male circumcision in the United States for the prevention of HIV infection and other adverse health outcomes: report from a CDC consultation. Public Health Rep. 125, 72-82.
220. Smith, R. M., Carrico, A. W., Montandon, M., Kwena, Z., Bailey, R., Bukusi, E. A., and Cohen, C. R. (2011). Attitudes and beliefs about anti-retroviral therapy are associated with high risk sexual behaviors among the general population of Kisumu, Kenya. AIDS Care 23, 1668-1675.
221. Steward, W. T., Bharat, S., Ramakrishna, J., Heylen, E., and Ekstrand, M. L. (2012). Stigma is associated with delays in seeking care among HIV-infected people in India. J. Int. Assoc. Physicians AIDS Care (Chic.). doi: 10.1177/1545109711432315. [Epub ahead of print].
222. Stover, J., Korenromp, E. L., Blakley, M., Komatsu, R., Viisainen, K., Bollinger, L., and Atun, R. (2011). Long-term costs and health impact of continued global fund support for antiretroviral therapy. PLoS ONE 6:e21048. doi: 10.1371/journal.pone.0021048
223. Sullivan, N. L., Eickhoff, C. S., Zhang, X., Giddings, O. K., Lane, T. E., and Hoft, D. F. (2011). Importance of the CCR5-CCL5 axis for mucosal Trypanosoma cruzi protection and B cell activation. J. Immunol. 187, 1358-1368.
224. Swan, H., and O'Connell, D. J. (2011). The impact of intimate partner violence on women's condom negotiation efficacy. J. Interpers. Violence 27, 775-792.
225. Tao, W., Richards, C., and Hamer, D. (2008). Enhancement of HIV infection by cellulose sulfate. AIDS Res. Hum. Retroviruses 24, 925-929.
226. Tapert, S. F., Aarons, G. A., Sedlar, G. R., and Brown, S. A. (2001). Adolescent substance use and sexual risk-taking behavior. J. Adolesc. Health 28, 181-189.
227. Torrone, E. A., Wright, J., Leone, P. A., and Hightow-Weidman, L. B. (2010). Pregnancy and HIV infection in young women in North Carolina. Public Health Rep. 125, 96-102.
228. Totrov, M., Jiang, X., Kong, X. P., Cohen, S., Krachmarov, C., Salomon, A., Williams, C., Seaman, M. S., Abagyan, R., Cardozo, T., Gorny, M. K., Wang, S., Lu, S., Pinter, A., and Zolla-Pazner, S. (2010). Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. Virolog y 405, 513-523.
229. Tovey, M. G., and Lallemand, C. (2010). Adjuvant activity of cytokines. Methods Mol. Biol. 626, 287-309.
230. Tritto, E., Mosca, F., and De Gregorio, E. (2009). Mechanism of action of licensed vaccine adjuvants. Vaccine 27, 3331-3334.
231. Trkola, A., Purtscher, M., Muster, T., Ballaun, C., Buchacher, A., Sullivan, N., Srinivasan, K., Sodroski, J., Moore, J. P., and Katinger, H. (1996). Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70, 1100-1108.
232. Tsai, C. C., Follis, K. E., Grant, R., Sabo, A., Nolte, R., Bartz, C., Bischofberger, N., and Benveniste, R. (1994a). Comparison of the efficacy of AZT and PMEA treatment against acute SIVmne infection in macaques. J. Med. Primatol. 23, 175-183.
233. Tsai, C. C., Follis, K. E., Sabo, A., Grant, R. F., Bartz, C., Nolte, R. E., Benveniste, R. E., and Bischofberger, N. (1994b). Preexposure prophylaxis with 9-(2-phosphonylmethoxyethyl)adenine against simian immunodeficiency virus infection in macaques. J. Infect. Dis. 169, 260-266.
234. Tudor Car, L., Van-Velthoven, M. H., Brusamento, S., Elmoniry, H., Car, J., Majeed, A., and Atun, R. (2011). Integrating prevention of mother-to-child HIV transmission (PMTCT) programmes with other health services for preventing HIV infection and improving HIV outcomes in developing countries. Cochrane Database Syst. Rev. CD008741.
235. Tuen, M., Visciano, M. L., Chien, P.C. Jr., Cohen, S., Chen, P. D., Robinson, J., He, Y., Pinter, A., Gorny, M. K., and Hioe, C. E. (2005). Characterization of antibodies that inhibit HIV gp120 antigen processing and presentation. Eur. J. Immunol. 35, 2541-2551.
236. Tyerman, Z., and Aboulafia, D. M. (2012). Review of screening guidelines for non-AIDS-defining malignancies: evolving issues in the era of highly active antiretroviral therapy. AIDS Rev. 14, 3-16.
237. Van Damme, L., Govinden, R., Mirembe, F. M., Guedou, F., Solomon, S., Becker, M. L., Pradeep, B. S., Krishnan, A. K., Alary, M., Pande, B., Ramjee, G., Deese, J., Crucitti, T., and Taylor, D. (2008). Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 359, 463-472.
238. van der Straten, A., Van Damme, L., Haberer, J. E., and Bangsberg, D. R. (2012). How well does PREP work? Unraveling the divergent results of PrEP trials for HIV prevention. AIDS 26, F13-F19.
239. Van Regenmortel, M. H. (2011). Limitations to the structure-based design of HIV-1 vaccine immunogens. J. Mol. Recognit. 24, 741-753.
240. Van Regenmortel, M. H. (2012). Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine. Arch. Virol. 157, 1-20.
241. Vermund, S. H., Hodder, S. L., Justman, J. E., Koblin, B. A., Mastro, T. D., Mayer, K. H., Wheeler, D. P., and El-Sadr, W. M. (2010). Addressing research priorities for prevention of HIV infection in the United States. Clin. Infect. Dis. 50, S149-S155.
242. Vlahov, D., Robertson, A. M., and Strathdee, S. A. (2010). Prevention of HIV infection among injection drug users in resource-limited settings. Clin. Infect. Dis. 50, S114-S121.
243. Voelker, R. (2011). HIV/AIDS funding dropped by 10% in 2010. JAMA 306, 1642-1643.
244. von Wyl, V., Yerly, S., Boni, J., Shah, C., Cellerai, C., Klimkait, T., Battegay, M., Bernasconi, E., Cavassini, M., Furrer, H., Hirschel, B., Vernazza, P. L., Ledergerber, B., and Gunthard, H. F. (2011). Incidence of HIV-1 drug resistance among antiretro-viral treatment-naive individuals starting modern therapy combinations. Clin. Infect. Dis. 54, 131-140.
245. Walensky, R. P., Paltiel, A. D., Losina, E., Morris, B. L., Scott, C. A., Rhode, E. R., Seage, G. R., and Freedberg, K. A. (2010). Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington, D.C. Clin. Infect. Dis. 51, 392-400.
246. Walker, L. M., and Burton, D. R. (2010). Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 22, 358-366.
247. Walker, L. M., Huber, M., Doores, K. J., Falkowska, E., Pejchal, R., Julien, J. P., Wang, S. K., Ramos, A., Chan-Hui, P. Y., Moyle, M., Mitcham, J. L., Hammond, P. W., Olsen, O. A., Phung, P., Fling, S., Wong, C. H., Phogat, S., Wrin, T., Simek, M. D., Koff, W. C., Wilson, I. A., Burton, D. R., and Poignard, P. (2011). Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470.
248. Walker, L. M., Phogat, S. K., Chan-Hui, P. Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., Lehrman, J. K., Priddy, F. H., Olsen, O. A., Frey, S. M., Hammond, P. W., Protocol G Principal Investigators, Kaminsky, S., Zamb, T., Moyle, M., Koff, W. C., Poignard, P., and Burton, D. R. (2009). Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289.
249. Wamai, R. G., Morris, B. J., Bailis, S. A., Sokal, D., Klausner, J. D., Appleton, R., Sewankambo, N., Cooper, D. A., Bongaarts, J., De Bruyn, G., Wodak, A. D., and Banerjee, J. (2011). Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa. J. Int. AIDS Soc. 14, 49.
250. Wasswa, H. (2011). Ugandan AIDS care workers realign strategies as Global Fund cuts grants. BMJ 343, d8018.
251. Wege, A. K., Melkus, M. W., Denton, P. W., Estes, J. D., and Garcia, J. V. (2008). Functional and phenotypic characterization of the humanized BLT mouse model. Curr. Top. Microbiol. Immunol. 324, 149-165.
252. Wei, C., Raymond, H. F., McFarland, W., Buchbinder, S., and Fuchs, J. D. (2011). What is the potential impact of adult circumcision on the HIV epidemic among men who have sex with men in San Francisco? Sex Transm. Dis. 38, 353-355.
253. Weli, S. C., and Tryland, M. (2011). Avipoxviruses: infection biology and their use as vaccine vectors. Virol. J. 8, 49.
254. White, T. A., Bartesaghi, A., Borgnia, M. J., De La Cruz, M. J., Nandwani, R., Hoxie, J. A., Bess, J. W., Lifson, J. D., Milne, J. L., and Subramaniam, S. (2011). Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins getermined by using cryo-electron tomography. J. Virol. 85, 12114-12123.
255. Wilkin, T. J., Su, Z., Krambrink, A., Long, J., Greaves, W., Gross, R., Hughes, M. D., Flexner, C., Skolnik, P. R., Coakley, E., Godfrey, C., Hirsch, M., Kuritzkes, D. R., and Gulick, R. M. (2010). Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. J. Acquir. Immune. Defic. Syndr. 54, 470-476.
256. Winskell, K., Hill, E., and Obyerodhyambo, O. (2011). Comparing HIV-related symbolic stigma in six African countries: social representations in young people's narratives. Soc. Sci. Med. 73, 1257-1265.
257. Winstone, N., Wilson, A. J., Morrow, G., Boggiano, C., Chiuchiolo, M. J., Lopez, M., Kemelman, M., Ginsberg, A. A., Mullen, K., Coleman, J. W., Wu, C. D., Narpala, S., Ouellette, I., Dean, H. J., Lin, F., Sardesai, N. Y., Cassamasa, H., McBride, D., Felber, B. K., Pavlakis, G. N., Schultz, A., Hudgens, M. G., King, C. R., Zamb, T. J., Parks, C. L., and McDermott, A. B. (2011). Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen. J. Virol. 85, 9578-9587.
258. Wirtz, V. J., Forsythe, S., Valencia-Mendoza,A., and Bautista-Arredondo, S. (2009). Factors influencing global antiretro-viral procurement prices. BMC Public Health 9, S6.
259. Wiysonge, C. S., Kongnyuy, E. J., Shey, M., Muula, A. S., Navti, O. B., Akl, E. A., and Lo, Y. R. (2011). Male circumcision for prevention of homosexual acquisition of HIV in men. Cochrane Database Syst. Rev. CD007496.
260. Wu, X., Yang, Z. Y., Li, Y., Hogerkorp, C. M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., Longo, N. S., McKee, K., O'Dell, S., Louder, M. K., Wycuff, D. L., Feng, Y., Nason, M., Doria-Rose, N., Connors, M., Kwong, P. D., Roederer, M., Wyatt, R. T., Nabel, G. J., and Mascola, J. R. (2010). Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861
261. Wu, X., Zhou, T., Zhu, J., Zhang, B., Georgiev, I., Wang, C., Chen, X., Longo, N. S., Louder, M., McKee, K., O'Dell, S., Perfetto, S., Schmidt, S. D., Shi, W., Wu, L., Yang, Y., Yang, Z. Y., Yang, Z., Zhang, Z., Bonsignori, M., Crump, J. A., Kapiga, S. H., Sam, N. E., Haynes, B. F., Simek, M., Burton, D. R., Koff, W. C., Doria-Rose, N. A., Connors, M., NISC Comparative Sequencing Program, Mullikin, J. C., Nabel, G. J., Roederer, M., Shapiro, L., Kwong, P. D., and Mascola, J. R. (2011). Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333, 1593-1602
262. Xiao, P., Patterson, L. J., Kuate, S., Brocca-Cofano, E., Thomas, M. A., Venzon, D., Zhao, J., DiPasquale, J., Fenizia, C., Lee, E. M., Kalisz, I., Kalyanaraman, V. S., Pal, R., Montefiori, D., Keele, B. F., and Robert-Guroff, M. (2012). Replicating adenovirus-SIV recom-binant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low dose rectal SIVmac251 challenge. J. Virol. 86, 4644-4657.
263. Xiao, X., Chen, W., Feng, Y., Zhu, Z., Prabakaran, P., Wang, Y., Zhang, M. Y., Longo, N. S., and Dimitrov, D. S. (2009). Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 390, 404-409
264. Yehia, B., and Frank, I. (2011). Battling AIDS in America: an evaluation of the National HIV/AIDS Strategy. Am. J. Public Health 101, e4-e8
265. Zablotska, I. B., Prestage, G., Holt, M., Poynten, M., De Wit, J., Guy, R., Mao, L., McAllister, J., and Grulich, A. E. (2011). Australian gay men who have taken nonoccupational postexposure prophylaxis for HIV are in need of effective HIV prevention methods. J. Acquir. Immune. Defic. Syndr. 58, 424-428.
266. Zhou, T., Georgiev, I., Wu, X., Yang, Z. Y., Dai, K., Finzi, A., Kwon, Y. D., Scheid, J. F., Shi, W., Xu, L., Yang, Y., Zhu, J., Nussenzweig, M. C., Sodroski, J., Shapiro, L., Nabel, G. J., Mascola, J. R., and Kwong, P. D. (2010). Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-817
267. Zolla-Pazner, S., Cardozo, T., Decamp, A., Haynes, B., Kim, J., Kong, X., Michael, N., Rerks-Ngarm, S., and Williams, C. (2011a). "V2-reactive antibodies in RV-144 vacci-nees' plasma," in AIDS Vaccine 2011 Conference (Bankok, Thailand).
268. Zolla-Pazner, S., Kong, X. P., Jiang, X., Cardozo, T., Nadas, A., Cohen, S., Totrov, M., Seaman, M. S., Wang, S., and Lu, S. (2011b). Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. J. Virol. 85, 9887-9898.
269. Zwick, M. B., Labrijn, A. F., Wang, M., Spenlehauer, C., Saphire, E. O., Binley, J. M., Moore, J. P., Stiegler, G., Katinger, H., Burton, D. R., and Parren, P. W. (2001). Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75, 10892-10905.